INDUSTRY × Leukemia, Myelomonocytic, Chronic × 1 year × Clear all
NCT04996875 2026-05-05

APEX

Cogent Biosciences, Inc.

Phase 2 Recruiting
140 enrolled
NCT05665530 2026-01-26

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Prelude Therapeutics

Phase 1 Completed
86 enrolled